<DOC>
	<DOC>NCT02282670</DOC>
	<brief_summary>This is a multicenter, active-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy and safety of DA-5204 and to demonstrate the non-inferiority of DA-5204 compared with StillenÂ® tab. in patients with acute or chronic gastritis.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of DA-5204</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Gastritis, Atrophic</mesh_term>
	<criteria>Age is over 20 years old, under 75 years old, men or women Patients diagnosed with acute or chronic gastritis by gastroscopy Patients with one or more erosions found by gastroscopy Signed the informed consent forms Patients who is impossible to receive gastroscopy Patients with peptic ulcer and gastroesophageal reflux disease Patients administered with prokinetics, H2 receptor antagonists, proton pump inhibitors, anticholinergic drugs or nonsteroid antiinflammatory drugs prior to study in 2 weeks Patients with surgery related to gastroesophageal Patients with ZollingerEllison syndrome Patients with any kind of malignant tumor Patients administered with antithrombotic drugs Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or endocrine system primary disease Patients with neuropsychiatric disorder, alcoholism, or drug abuse Patients taking other investigational drugs or participating in other clinical studies in 4 weeks. Women either pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>